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1.

Introduction
Treatment of metastatic renal cell carcinoma (mRCC) has greatly improved over the past decade with the introduction of targeted therapies acting on vascular endothelial growth factor receptor (VEGFR) or mammalian target of rapamycin (mTOR) [1] . However, as most patients experience disease progression during treatment with targeted therapy, sequential treatment with different agents has become standard practice [2, 3] . Choosing the sequence of agents to optimise outcomes remains a key clinical challenge [3, 4] . Sorafenib and sunitinib are multikinase inhibitors with overlapping but not identical kinase inhibition profiles. They target VEGFR 1-3, platelet-derived growth factor receptor, and c-Kit [5, 6] ; sorafenib also targets BRAF and RET [6] . Both are approved for the treatment of mRCC in first-line (sunitinib) and cytokine-unsuitable (sorafenib) settings; sorafenib has shown efficacy in multiple treatment lines [2, [7] [8] [9] [10] [11] .
In retrospective studies, sequential use of sorafenib and sunitinib in mRCC was well tolerated and provided additional clinical benefit beyond the use of either agent alone; these retrospective studies suggested that outcomes could be better with sorafenib followed by sunitinib (So-Su) compared with sunitinib followed by sorafenib (Su-So) [3, [12] [13] [14] [15] [16] . The largest retrospective analysis at the time when the present study was designed (n = 189) revealed a numerically longer progression-free survival (PFS) for So-Su than for Su-So (17.2 vs 11.7 mo) [15, 17] . SWITCH was the first prospective, randomised, phase 3 study to test the hypothesis that sequential therapy with So-Su is superior to Su-So in prolonging total PFS (defined as time from randomisation to confirmed progression or death during second-line therapy) in advanced/metastatic RCC.
2.
Patients and methods Patients were randomised to sorafenib 400 mg twice daily followed by sunitinib 50 mg once daily (4 wk on, 2 wk off) (So-Su) or vice versa (Su-So). The treatment cycle length was 6 wk for both sorafenib and sunitinib. Dose modifications to manage adverse events (AEs) were permitted at the discretion of the investigator; the protocol included recommendations on when and how to implement dose reductions, interruptions, and permanent discontinuations. The sorafenib dose could be reduced to 400 mg once daily and then 400 mg every other day.
Study design and patients
The sunitinib dose could be reduced to 37.5 mg once daily and then 25 mg once daily. Randomisation was stratified by MSKCC score (favourable vs intermediate). Centralised randomisation via fax was coordinated by iOMEDICO AG (Germany). The randomisation list was generated by ICRC Weyer GmbH using an SAS program. The person who generated the randomisation list was not involved in the study project management, monitoring, or data management.
First-line treatment in both arms continued until disease progression according to RECIST or intolerable toxicity (after unsuccessful dose reduction/interruption). There was a treatment-free crossover period of 1-4 wk after first-line treatment to avoid additive toxicity. Patients who discontinued first-line treatment because of toxicity began second-line treatment only after nonhaematological toxicity had resolved to grade 1 and haematological toxicity to grade 2. Patients who refused further first-line treatment because of toxicity could begin second-line treatment if they consented and were in general compliance with the study protocol.
Study endpoints and assessments
Supplementary 
Results
Patients
From February 2009 to December 2011, 365 patients were randomised (182 to So-Su; 183 to Su-So) at 72 centres in Germany, Austria, and the Netherlands (Fig. 1) . Patient demographics and baseline characteristics were well balanced between the treatment groups ( Table 1) . Although the study protocol mandated that patients should not have received prior treatment and should be unsuitable for cytokines, seven patients had prior interferon-a and four patients had prior interleukin-2. These patients were included in the analyses under the intention-to-treat principle. At data cutoff for all analyses (August 15, 2013), the mean follow-up (from last treatment to end of follow-up) was 10.3 mo. Overall, 353 (97%) patients received first-line treatment and 179 (49%) patients received second-line treatment. More patients reached protocol-defined second-line therapy in the So-Su arm (n = 103, 57%) than in the Su-So arm (n = 76, 42%; p < 0.01; Fig. 1 ). When the 13 So-Su and 24 Su-So patients receiving documented, non-protocol-defined second-line therapy were included, the difference was no longer statistically significant (n = 116 [64%] vs n = 100 [55%]; p = 0.09). Of the 103 So-Su patients and 76 Su-So patients who received perprotocol first-and second-line therapy, 52 and 36 patients, respectively, went on to receive further treatment. Subsequent therapy for patients who discontinued the study after first-line therapy and for those who received both first-and second-line therapy is detailed in Supplementary Table 3 , and typically included mTOR inhibitors (everolimus and temsirolimus) and VEGF(R) inhibitors (bevacizumab/ interferon, pazopanib, sunitinib, sorafenib). Some patients received second-line sorafenib or sunitinib outside of the study protocol, mostly because of a treatment break longer than the protocol-specified 28 d. In both groups, the most common reason for stopping first-line therapy was disease progression. The most frequent reasons for not initiating protocol-defined second-line treatment after stopping first-line treatment were death Fig. 1 ). Demographic and baseline characteristics were generally similar between patients who received first-line therapy only and those who received both first-and second-line therapy, although patients not progressing to second-line therapy typically had a less favourable MSKCC score and ECOG PS and more previous treatment; in addition, fewer patients had undergone nephrectomy and more had non-clear-cell histology (Supplementary Table 4 ).
Efficacy
At data cutoff (August 15, 2013), the primary objective was not met: So-Su was not superior to Su-So in terms of PFS (median 12.5 vs 14.9 mo; HR 1.01, 90% CI 0.81-1.27; p = 0.5 for superiority; Fig. 2A ). OS was similar in both arms (median 31.5 mo for So-Su and 30.2 mo for Su-So; HR 1.00, 90% CI 0.77-1.30; p = 0.5 for superiority; Fig. 2B ). Median follow-up for patients without an OS event was 1.4 mo for So-Su and 3.0 mo for Su-So. Median first-line PFS was also similar between the two groups (5.9 mo for So-Su vs 8.5 mo for Su-So; HR 1.19, 90% CI 0.97-1.47; p = 0.9 for superiority; Fig. 3a) . Median second-line PFS was longer for So-Su than for Su-So (5.4 vs 2.8 mo; HR 0.55, 90% CI 0.41-0.74; p < 0.001 for superiority; Fig. 3B ). ORR and DCR were similar during first-line treatment with sorafenib and sunitinib. During second-line treatment, ORR and DCR were higher for sunitinib than for sorafenib (p = 0.03 for DCR; Table 2 ). Median time to first-line treatment failure (6.0 vs 9.0 mo; HR 1.15, 90% CI 0.93-1.42; p = 0.9 for superiority) and median total TTP (15.2 vs 17.2 mo; HR 1.01, 90% CI 0.79-1.30; p = 0.5 for superiority) were comparable between the So-Su and Su-So groups. Updated survival analysis (data cutoff January 14, 2014) revealed median OS of 30.0 mo for So-Su and 27.4 mo for Su-So (HR 0.99, 90% CI 0.77-1.27; p = 0.5 for superiority; Supplementary Fig. 1 ) [19] .
Efficacy findings in the per-protocol population were generally consistent with those in the ITT population (data not shown), except for the interim OS analysis (31.5 
In the updated analysis, median OS in the per-protocol population (31.5 mo for So-Su vs 30.2 mo for Su-So; HR 1.06, 90% CI 0.81-1.40; p = 0.6 for superiority) was again consistent with that in the ITT population.
Safety
The safety population included 177 So-Su patients and 176 Su-So patients who received at least one dose of firstline study treatment. The safety results are summarised in Table 3 . The mean duration of first-line therapy was not significantly different between sorafenib and sunitinib (log rank test p = 0.1). During second-line treatment, the mean duration of therapy was shorter for sorafenib (Su-So arm) than for sunitinib (So-Su arm; log rank test p < 0.001). The mean (AE standard deviation) treatment break between firstand second-line therapy (excluding the regular 2-wk interval after sunitinib) was 21 AE 16 d for So-Su and 17 AE 14 d for Su-So (p = 0.1). The most common treatment-emergent AEs were diarrhoea, hand-foot skin reaction, hypertension, and fatigue for first-line sorafenib, and diarrhoea, fatigue, hypertension, and nausea for first-line sunitinib. Withdrawal because of AEs during first-line treatment was significantly more frequent in the Su-So arm (n = 52, 30%) than in the So-Su arm (n = 33, 19%; p = 0.02). Cardiac safety parameters (LVEF and NT-proBNP) were similar between the groups at all three assessment visits (Supplementary Table 5 ).
Post hoc subgroup analyses
Median total PFS and median first-line PFS were generally similar between the treatment arms across patient subgroups categorised according to age, sex, ECOG PS, and MSKCC score. Differences in median OS reached statistical significance in subgroups split according to age, with greater benefits observed for So-Su in patients aged >65 yr (HR 0.60, 95% CI 0.37-0.97) and for Su-So in patients aged 65 yr (HR 1.57, 95% CI 1.01-2.44). No other significant differences in OS were observed between subgroups (Fig. 4) . In the updated OS analysis (cutoff January 14, 2014), the only significant difference between post hoc subgroups was that patients aged >65 yr experienced a greater benefit with So-Su than Su-So (median OS 31.5 vs 19.8 mo; p = 0.04; Supplementary Table 6) [19] . To explore possible reasons for the apparent improved OS in older patients who received So-Su compared with Su-So, the number of patients aged 65 or >65 yr who received each treatment line, the duration of treatment for each line, and the incidence of grade 3/4 AEs were determined (Supplementary Table 7 ). In patients aged >65 yr, the mean duration of first-line treatment was similar in each treatment arm (35.7 wk So-Su vs 39.8 wk Su-So, p = 0.6); the mean duration of second-line treatment was 36.0 wk with So-Su and 12.9 wk with Su-So (p < 0.0001). Rates of grade 3/4 AEs tended to be higher with sunitinib than with sorafenib in both the first and second lines of treatment (first line, Su-So 67% vs So-Su 55%, p = 0.1; second line, So-Su 55% vs Su-So 26%, p = 0.02). Presented for the safety population, So-Su n = 177, Su-So n = 176, total n = 353. c Some patients received more than one previous cancer treatment. For two of the patients assigned to the Su-So group, the information was missing. [20] . First-line PFS for each agent in SWITCH (sorafenib 5.9 mo; sunitinib 8.5 mo) was within the previously reported range (4.4-11.6 mo for sorafenib and 5.1-13.1 mo for sunitinib) [10, 15, 16, [21] [22] [23] . Second-line PFS with sorafenib following first-line sunitinib in the phase 3 INTORSECT and AXIS studies (3.9 and 3.4 mo, respectively) [8, 11] was also consistent with that seen in SWITCH (2.8 mo). Both first-and second-line PFS in SWITCH were consistent with results from the largest retrospective study reported to date (n = 2106 across multiple centres) [24] . In that study, Alimohamed et al reported first-line PFS of 7.3 mo for sorafenib (n = 412) and 7.2 mo for sunitinib (n = 1542), and second-line PFS of 3.6 mo for sorafenib following sunitinib (n = 257), and 5.2 mo for sunitinib following sorafenib (n = 152) [24] . In SWITCH, second-line PFS for sunitinib following sorafenib was 5.4 mo. In their large retrospective study, Alimohamed et al concluded that the sequence in which targeted therapies are used does not substantially affect clinical outcome [24] . While our PFS findings confirm this observation, response rates appeared to differ for the treatment sequences. ORR (31% and 29%) and DCR (69% and 64%) were similar for first-line sorafenib and sunitinib, respectively. However, compared with patients receiving Su-So, those receiving So-Su had greater second-line ORR (17% vs 6.6%) and DCR (49% vs 32%). The clinical relevance of these observations remains unclear, particularly in the context of our PFS findings.
Discussion
To the best of our knowledge, no other phase 3 studies of sequential TKI therapy in RCC have been reported. Findings of a phase 2 study (RECORD-3) investigating sequential everolimus followed by sunitinib (Ev-Su) compared with Fig. 2 -Kaplan-Meier plots of (A) total progression-free survival and (B) overall survival (intention-to-treat population). CI = confidence interval; HR = hazard ratio; PFS = progression-free survival; OS = overall survival; So = sorafenib; Su = sunitinib. sunitinib followed by everolimus (Su-Ev) were recently published [25] . Median total PFS was 21.1 mo for Ev-Su and 25.8 mo for Su-Ev (HR 1.3, 95% CI 0.9-1.7) and OS was 22.4 mo for Ev-Su and 32.0 mo for Su-Ev (HR 1.2, 95% CI 0.9-1.6). Notably, 207 patients (44%) overall in RECORD-3 received per-protocol second-line treatment, similar to the proportion of patients who received secondline treatment in our study (179 patients, 49%).
One key challenge in managing mRCC is that only approximately half of patients proceed from first-line to second-line treatment. In the present study, more patients reached second-line therapy on protocol in the So-Su compared with the Su-So arm (57% vs 42%; p < 0.01). This is consistent with data from other studies suggesting that patients receiving sorafenib early in the treatment sequence are more likely to receive subsequent therapies than those receiving first-line sunitinib (34-38% for sorafenib vs 16-18% for sunitinib) [26, 27] . The reasons for this difference are not clear. Notably, patients in our study who did not progress to second-line therapy happened to have more advanced disease (less favourable MSKCC score and ECOG PS; more prior treatment) or poorer prognosis (fewer patients had undergone nephrectomy; more with nonclear-cell histologies) than those who did progress to second-line therapy. Furthermore, differences in the firstline AE profiles may impact patients' willingness or ability (31) 51 (29) 18 (17) Dose reductions, n (%) 65 (37) 24 (23) 65 (37) 
to continue to second-line treatment, as has been shown elsewhere [28, 29] . The most common reasons cited by investigators for not continuing to second-line treatment in SWITCH in the So-Su versus Su-So arms, respectively, were death (16% vs 19%), AEs (8% versus 17%), and withdrawn consent (9% vs 13%). Safety profiles differed between sorafenib and sunitinib, but were generally as expected and consistent with previous reports for these agents in patients with mRCC [30, 31] . AEs were generally less frequent during second-line than first-line therapy. Although the precise reasons are not known, this observation is consistent with previous data showing that AEs tend to occur early in the course of TKI therapy [32, 33] , and suggests possible cross-tolerance and adaptation to TKI treatment. Prospective assessment of cardiac safety (LVEF and NT-proBNP values) was included in the protocol following previous reports of cardiotoxicity and reduced LVEF, particularly with sunitinib [30, [34] [35] [36] [37] [38] . For example, a meta-analysis found a higher risk of all-grade and high-grade congestive heart failure, mainly defined as declines in LVEF, in sunitinib-treated compared with placebo-treated renal and nonrenal cancer patients [38] . In addition to monitoring and managing hypertension, which may be associated with cardiac events in patients receiving TKIs [35, 37] , NT-proBNP represents a more convenient and potentially more reliable early marker of cardiac damage than LVEF [39, 40] . Results for LVEF and NT-proBNP monitoring in SWITCH indicated that neither sorafenib nor sunitinib significantly affected cardiac safety. This is consistent with findings from an ongoing phase 3, 
randomised, placebo-controlled study of adjuvant sorafenib or sunitinib in patients with resected, nonmetastatic RCC at high risk of recurrence (NCT00326898). In that study, LVEF declines were negligible, occurring in only 2.3%, 1.8%, and 1.0% of patients receiving sunitinib, sorafenib, and placebo, respectively [41] . Subgroup analyses for age, sex, risk of recurrence, and baseline performance status (ECOG PS 0 vs 1) revealed no differences between So-Su and Su-So in terms of total PFS, OS, or first-line PFS apart from statistically significant differences in OS according to age, with the results favouring So-Su in patients aged >65 yr (Fig. 4B and Supplementary Table 6 ) [19] . The reasons for this difference are unclear. The study design did not include patient stratification according to age, and our observations should be considered as hypothesis-generating only. Nonetheless, it is interesting that sorafenib appeared to be somewhat better tolerated than sunitinib in elderly patients in our study. Indeed, age was included in our subgroup analyses as previous analyses suggested that sorafenib is effective and well tolerated particularly in elderly patients [33, [42] [43] [44] .
The study has a number of limitations to be considered when interpreting the results. The study was open-label rather than double-blind, introducing a potential for investigator bias; however, the protocol mandated that confirmed radiologic progression was required to stop treatment on the grounds of disease progression, which reduced this potential for bias. The findings for second-line PFS may not be robust because there were low numbers of patients/ events; fewer patients received on-study second-line treatment with sunitinib compared with sorafenib; and only selected subsets of patients were able to receive secondline treatment. The results for second-line therapy should therefore be interpreted with caution. OS could have been confounded by subsequent treatments received after patients completed per-protocol therapy. Limited prospective sequential data were available at the time at which the study was designed, so it was not possible to estimate the impact that an imbalance in discontinuation could have on the study findings, particularly in terms of total PFS and second-line PFS. The different safety profiles of sorafenib and sunitinib may have contributed to differences in first-line therapy discontinuation, and thus affected first-line PFS and total PFS. In sequential studies, the decision to end first-line treatment can potentially be influenced by investigator knowledge that a second-line treatment is readily available. In SWITCH, however, confirmed radiologic progression was required to proceed to second-line treatment.
Conclusions
SWITCH is the first prospective, randomised, phase 3 study of sequential TKI therapy (So-Su vs Su-So) for advanced/ metastatic RCC; 49% of patients received per-protocol second-line therapy. The primary endpoint of total PFS was not met, but the results did confirm the clinical benefit of sequential treatment, with median OS of approximately 30 mo. Further prospective randomised studies investigating the optimal sequencing of targeted agents are ongoing. Statistical analysis: Gottstein.
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